Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 25;33(10):529-540.
doi: 10.1093/intimm/dxab061.

Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021

Kun Xu  1 , Lianpan Dai  1   2 , George F Gao  2
Affiliations
Review

Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021

Kun Xu et al. Int Immunol. .

Abstract

Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.

Keywords: SARS-CoV-2; T cell; antibody; variant.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Timeline showing the key time point of initiating clinical trials and use authorizations for the vaccines against COVID-19.
Fig. 2.
Fig. 2.
Schematic representation of the induced immune response following SARS-CoV-2 infection. The gray, blue, green and brown lines indicate upper respiratory tract (URT) virus load, T-cell responses, IgM level and IgG level, respectively.
See this image and copyright information in PMC

References

    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int.
    1. Tan, W., Zhao, X., Ma, X.et al. 2020. A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019–2020. China CDC Weekly 2:61. - PMC - PubMed
    1. Stenseth, N. C., Dharmarajan, G., Li, R.et al. 2021. Lessons learnt from the COVID-19 pandemic. Front. Public Health 9:694705. - PMC - PubMed
    1. Dai, L. and Gao, G. F. 2021. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21:73. - PMC - PubMed
    1. Wang, H., Zhang, Y., Huang, B.et al. 2020. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182:713. - PMC - PubMed

Publication types

Substances